Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...
A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.
7don MSN
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
IF YOU SUFFERED A LOSS ON YOUR MOONLAKE IMMUNOTHERAPEUTICS (MLTX) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS ...
Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman. MLTX Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO ...
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...
The MoonLake class action lawsuit alleges that on September 28, 2025, MoonLake announced 16-week results from its Phase 3 VELA program which showed that SLK failed to demonstrate competitive efficacy ...
B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback